ArticleApplied microbiology and biotechnology2025
Development of antibodies against severe fever with thrombocytopenia syndrome virus nucleoprotein for diagnosis.
Article in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Multidimensional mechanisms of SFTSV-host interactions: viral protein functions, mFrontiers in cellular and infection microbiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Severe fever with thrombocytopenia syndrome (SFTS) is an emerging viral infectious disease caused by a novel Bandavirus in the family Phenuiviridae. The SFTS virus (SFTSV) is transmitted to various hosts, including humans, through tick bites, leading to high fever, thrombocytopenia, and leukopenia, with a high case fatality rate (up to 30%) due to multiple organ dysfunction. Therefore, early diagnosis is crucial for effective treatment and preventing disease transmission. In this study, we aimed to develop and characterize monoclonal antibodies targeting the SFTSV nucleocapsid protein (NP). We generated recombinant NP to screen antibodies against SFTSV. Using phage display technology, we identified candidate single-chain variable fragment (scFv) sequences capable of detecting SFTSV NP. Five human IgG antibodies and six chimeric mouse antibodies exhibited strong binding ability to the recombinant NP. Furthermore, their specificity and selectivity were evaluated against NPs from different subtypes and other viral species. A sandwich enzyme-linked immunosorbent assay (ELISA) was performed to determine optimal antibody pairings for SFTSV detection. The mP01A05/hP01C09, mP01A05/hP01B10, and mP02E04/hP01A05 antibody pairs demonstrated high efficacy in diagnosing SFTSV infections. These findings provide valuable antibody resources and establish an effective platform for the diagnosis of SFTS. KEY POINTS: • Monoclonal antibodies targeting SFTSV NP were developed using phage display technology. • Candidate antibodies showed strong binding ability and high specificity to SFTSV NP. • Optimized antibody pairs enabled effective SFTSV detection via sandwich ELISA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.